PhotoPill is developing a daily treatment solution, which will be effective in both treating inflammatory outbursts, as well as postponing future episodes.

Cupola is engaged in the development and commercialization of novel and non-invasive medical devices indicated for Tattoo and Pigment removal.
Cupola targets the Aesthetic market with this innovative solution.

ENT Surgical is developing a unique technology that will enable the performance of surgical insertion of ventilation tube to the eardrum (Myringotomy), within seconds, through usage of a single, all in one, medical device thus excluding the need for general anesthesia

CGM-3 is developing a sensor containing implant which will automatically and continuously monitor Glucose levels in Diabetes Type 1 patients, thus bridging the technological gap for an artificial Pancreas omitting Insulin.

Intratech medical is developing a novel solution for the treatment of Ischemic Stroke

JetPrep is engaged in the development and marketing of innovative medical devices for the Gastrointestinal (GI) market.

Remon Medical Technologies develops and commercializes smart, miniature implants which enable physicians to assess and treat a variety of medical conditions in a non-invasive manner. Remon's unique platform has broad applications for patient management. Remon Medical is backed by leading global investors including Concord Ventures, KBL Healthcare Ventures, Lilly Ventures, Medica Venture Partners, Ofer Hi-Tech, Polaris Venture Partners, Triathlon Medical Ventures, and Guidant Corporation.

EZSurgical develops innovative surgical tools aiming to assist the surgeon while performing general and minimal invasive (MIS) procedures.

EndoCross is developing a breakthrough technology for treating vascular occlusions.

Arbel Medical develops the next generation of Cryosurgery products and focuses first on the office-based treatment

AngioSlide is developing a breakthrough platform technology that both improves existing procedures and opens new applications in the field of interventional cardiology.

CorAssist is developing innovative therapeutic products for the treatment of diastolic heart failure. The company's platform technology, the ImCardia™ device, enables the first implantation of a device that directly improves cardiac diastolic function.

NanoPass develops highly competitive, painless MicroPyramid™ devices for drug delivery and diagnostics, which use the most advanced MEMS (micro electro-mechanical systems) bioengineering, as is used in silicon wafer micro-fabrication.

M.G.V. Systems is developing therapeutic protocols based on unique technologies involving the transfer of specific genes to vascular cells. This novel therapeutic protocol will provide effective treatment for patients who are beyond cure today.

THROMBOTECH is developing a series of new and improved thrombolytic agents that can easily dissolve newly formed blood clots without side effects. These new and innovative protocols can treat patients who previously had no treatment (stroke victims) and offer a better and safer mode of therapy for heart attack (acute myocardial infarction).

Enzymotec creates tailor-made and unique biocatalysts for enzymatic processes, yielding higher quality products and lower processing costs. The company’s patented AMIET® technology represents a breakthrough technological platform, which enhances any enzyme and enables it to efficiently perform in an organic media.

Barnev’s Computerized Labor Monitoring System, the CLM, enables obstetricians to make critical decisions based on accurate and timely information, resulting in significantly improved medical care, reduced costs and a lower risk of malpractice.

Common Sense Ltd. develops and manufactures nonintrusive home tests for classification of common abnormal vaginal discharges (the VI-SENSE Kit) and for detection of amniotic fluid leakage (the AL-SENSE Kit). Both products have received CE certification and are marketed throughout Europe.

NoriTech Seaweed Biotechnologies Ltd. is developing a revolutionary technology for the commercial cultivation of the edible seaweed Porphyra ("Nori") in on-land seawater ponds. The economic benefits of NoriTech's controlled cultivation system are its reliability in producing a pre-planned, standardized crop and its ability to enrich the algae with nutritional elements.

TK-Signal is developing revolutionary radiology-based compounds for diagnosing, monitoring and treating cancer. The company’s highly selective radioactive tracers are used in conjunction with nuclear medicine imaging techniques (PET) to specifically target the epidermal growth factor receptor.

Verto Medical is a biopharmaceutical company focused on the research and development of highly specific therapeutic products for the treatment of Systemic Lupus Erythematosus, a life-threatening antibody mediated disease.